Regulus Therapeutics (RGLS) Tops Q3 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- Grant Thornton Advisors to buy CBIZ in $5 billion deal, expand US accounting reach
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Regulus Reports Third Quarter 2015 Financial Results and Recent Highlights
November 5, 2015 4:06 PM ESTLA JOLLA, Calif., Nov. 5, 2015 /PRNewswire/ --Â Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results and highlights for the quarter ended September 30, 2015 and provided a summary of recent corporate highlights.Â
"Regulus' recent achievements reflect our steady progress in building a meaningful clinical portfolio based on microRNAs," said Paul Grint,... More
